Atorvastatin vs Ezetimibe: What to Choose and for Whom
Atorvastatin and ezetimibe are rarely true 'competitors': in most clinical situations the question is not 'which of the two' but 'where to start and when to add the second'. The editorial team explains how doctors build lipid-lowering therapy according to modern guidelines, for whom ezetimibe can become the main drug, and what is important to know for people who train regularly.
Treatment goal: the LDL target by risk
The starting point of any decision is the overall cardiovascular risk. The European ESC/EAS 2019 guidelines link each risk category to a specific LDL target. The higher the risk, the lower the target should be and the more intensive the therapy will be.
| Risk category | Examples | LDL target |
|---|---|---|
| Very high | Prior heart attack, stroke, stenting; diabetes with organ damage | <1.4 mmol/L and a reduction of ≥50% from baseline |
| High | Familial hypercholesterolemia, LDL >4.9 mmol/L, long-standing diabetes | <1.8 mmol/L and a reduction of ≥50% |
| Moderate | Young people with uncomplicated diabetes, moderate calculated risk | <2.6 mmol/L |
| Low | Low calculated risk by SCORE2 | <3.0 mmol/L |
Knowing the target and the baseline LDL, the doctor assesses by what percentage the level needs to be lowered. If a reduction of 30–40% is needed, a moderate-intensity statin is usually enough. If 50% or more — a high-intensity statin is needed, and often a combination as well.
This approach explains why a small dose of statin is enough for one person, while another needs two drugs at the maximum tolerated doses. Comparing your therapy with that of acquaintances without taking risk into account is incorrect.
It is also important to remember: the LDL target is not 'optimal well-being' but a reduction in the likelihood of a heart attack or stroke in the future. High cholesterol is usually not felt in any way.
A statin as the first step
For the vast majority of patients the first drug is a statin — for example, atorvastatin. Its benefit for reducing cardiovascular events has been proven in many large studies, in particular ASCOT-LLA and TNT, and the CTT meta-analysis (2010) showed a consistent relationship between LDL reduction and risk reduction.
Atorvastatin is convenient in that it covers both moderate and high intensity depending on the dose. The doctor chooses the starting dose by the required percentage of reduction, and after 6–8 weeks assesses the result with a lipid panel.
The first-line statin does not have to be atorvastatin: in a number of situations rosuvastatin is more appropriate, for example with many interactions via CYP3A4. However, the logic remains the same — first a statin at the maximum tolerated dose.
Starting therapy with ezetimibe on your own 'because it is milder' in high risk is not advisable: for ezetimibe monotherapy there are no studies with hard endpoints, and the strength of LDL reduction is moderate.
When ezetimibe is added
The ESC/EAS 2019 guidelines recommend adding ezetimibe if the LDL target is not reached at the maximum tolerated statin dose. This is the most common and best-justified scenario: in the IMPROVE-IT study such a combination after acute coronary syndrome reduced the frequency of cardiovascular events compared with statin monotherapy.
Increasing attention is being drawn to the early combination strategy — combining a moderate-intensity statin with ezetimibe instead of a high-intensity statin. In the RACING study (Kim et al., 2022) rosuvastatin 10 mg together with ezetimibe was non-inferior to rosuvastatin 20 mg for cardiovascular events, and discontinuation of therapy due to intolerance occurred less often. Although this study concerned rosuvastatin, it supports the very idea of a combined approach.
The combination is often produced as a single tablet, which improves adherence to treatment. For people who need an LDL reduction of 60% or more, it often becomes the starting choice.
If even the combination does not achieve the target, the next step is PCSK9 inhibitors or other modern drugs. This decision is made by a cardiologist or lipidologist.
Statin intolerance
Some patients complain of muscle symptoms while on statins. The EAS consensus (Stroes et al., 2015) recommends not abandoning statins immediately: first take a break, then re-try the same drug at a lower dose or a different statin, in particular with dosing every other day.
True complete statin intolerance occurs less often than is said about it. However, if it is confirmed, ezetimibe becomes an important drug of choice: it is well tolerated and does not cause the muscle problems inherent to statins.
In such cases ezetimibe is often combined with a minimal tolerated dose of statin — even a small dose gives additional benefit. If the target is unattainable, the doctor considers other agents.
- Do not stop taking a statin on your own because of muscle pain — discuss the symptoms with your doctor.
- Check your vitamin D level and thyroid function: hypothyroidism increases the risk of muscle complaints.
- Tell your doctor about all medications and supplements, especially those that affect CYP3A4.
Training and monitoring of tests
For physically active people it is important to distinguish ordinary post-workout soreness from statin-related symptoms. The latter are more often symmetrical, involve the large muscles of the thighs and shoulders, and do not go away after a few days of rest.
Creatine kinase after heavy workouts can rise several-fold without any medications. Therefore a baseline CK test before starting a statin is better taken after a few days without intense loads, and if myopathy is suspected — also after a break from training.
People who use anabolic steroids often have a pronounced reduction in HDL and an increase in LDL. A statin or ezetimibe does not compensate for the other risks of such drugs — from myocardial hypertrophy to erythrocytosis — and the strategy of 'covering' them with lipid-lowering agents is mistaken.
Standard monitoring of therapy includes a lipid panel 6–8 weeks after starting or changing the dose, ALT before starting and as indicated, and CK with muscle symptoms. Neither atorvastatin nor ezetimibe is on the WADA Prohibited List.
Editorial conclusions
For most people with indications for treatment the first step is a statin, in particular atorvastatin, and ezetimibe is added if the LDL target is not reached.
The early combination of a moderate-intensity statin with ezetimibe is a modern alternative to high doses of statins, especially when a significant LDL reduction is needed.
With confirmed statin intolerance, ezetimibe becomes a key drug, but for monotherapy with it there are no data on reducing heart attacks and strokes.
We described the pharmacological differences in the article 'Atorvastatin or Ezetimibe: What Is the Difference'. We also recommend 'Rosuvastatin vs Citrus Bergamot: What to Choose and for Whom' and the material on creatine kinase in athletes.
References
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
- Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397.
- Kim BK, Hong SJ, Lee YJ, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022;400(10349):380–390.
- LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–1435.
- Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy — European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012–1022.
- Cholesterol Treatment Trialists' (CTT) Collaboration; Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
- Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341–375.
Andriy Melnyk
A strength-sports coach and author of programs for beginner and intermediate levels. Writes about training planning.
